Featured Press Releases

ImmunityBio Announces FDA Approval of ANKTIVA®,

ImmunityBio Announces FDA Approval of ANKTIVA®,

LabConnect and Australian Clinical Labs

LabConnect and Australian Clinical Labs' Specialised Trials Announce a Strategic Partnership in the Australia and Asia Pacific Region

  • 23 Feb 2025

LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic...

Marking a new era of uncovering the potential of NAD+ with precision science, ChromaDex evolves into Niagen Bioscience

Marking a new era of uncovering the potential of NAD+ with precision science, ChromaDex evolves into Niagen Bioscience

enGene to Showcase Pivotal Phase 1/2 LEGEND Study Details of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

enGene to Showcase Pivotal Phase 1/2 LEGEND Study Details of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Study: BRENZAVVY® matches Dapagliflozin in Chinese type 2 diabetes

Study: BRENZAVVY® matches Dapagliflozin in Chinese type 2 diabetes

Endo

Endo's New Spatial Computing Injection Simulator for Peyronie's Disease Creates Immersive Learning Environment for Urology Specialists

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

Stablepharma Launches Phase 1 Trials for First-Ever Fridge-Free Tetanus & Diphtheria Vaccine

  • Stablepharma Ltd
  • 30 Apr 2025
Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

Xencor Announces Promising Early Results for XmAb942 in First-in-Human Study Targeting IBD

  • XENCOR, Inc.
  • 29 Apr 2025
Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

  • Bold Therapeutics Inc.
  • 28 Apr 2025
At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

  • Longhorn Vaccines and Diagnostics
  • 28 Apr 2025
Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

Innorna Announces FDA Grants Rare Pediatric Disease and Orphan Drug Designations to IN013 for Wilson Disease Treatment

  • Innorna Co. Ltd.
  • 28 Apr 2025
Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems Receives FDA Clearance for IND Application to Begin Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

  • Delcath Systems, Inc.
  • 28 Apr 2025

Most Popular
May   2025
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.